On December 12, 2025, BioCryst Pharmaceuticals announced FDA approval for a new oral pellet formulation of ORLADEYO® for pediatric patients (aged 2 to <12 years) with hereditary angioedema. This is the first oral prophylactic treatment approved for this age group.